# Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

> **NCT07162181** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 13 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
- B-cell Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT07162181
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2030-05
- **Final completion:** 2030-05
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162181, "Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07162181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*